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ABSTRACT
Background Statins inhibit hydroxymethylglutaryl-coenzyme A reductase, decrease plasma low-density lipo-
protein cholesterol and reduce cardiovascular morbidity and mortality. They can also exert adverse effects,
mostly affecting skeletal muscle, ranging from mild myalgia to rhabdomyolysis.
Materials and methods Based on a PubMed search until December 2014, this review summarizes studies on
statin effects on muscle mitochondrial morphology and function in the context of myopathy.
Results Possible mechanisms of statin-induced myopathy include lower cholesterol synthesis and production
of prenylated proteins, reduced dolichols and increased atrogin-1 expression. Statin-treated patients frequently
feature decreased muscle coenzyme Q10 (CoQ10) contents, suggesting that statins might impair mitochondrial
function. In cell cultures, statins diminish muscle oxygen consumption, promote mitochondrial permeability
transient pore opening and generate apoptotic proteins. Animal models confirm the statin-induced decrease in
muscle CoQ10, but reveal no changes in mitochondrial enzyme activities. Human studies yield contradictory
results, with decreased CoQ10, elevated lipids, decreased enzyme activities in muscle and impaired maximal
oxygen uptake in several but not all studies. Some patients are susceptible to statin-induced myopathy due to
variations in genes encoding proteins involved in statin uptake and biotransformation such as the solute carrier
organic anion transporter family member 1B1 (SLCO1B1) or cytochrome P450 (CYP2D6, CYP3A4, CYP3A5).
Carriers for carnitine palmitoyltransferase II deficiency and McArdle disease also present with higher prevalence
of statin-induced myopathy.
Conclusions Despite the widespread use of statins, the pathogenesis of statin-induced myopathy remains
unclear, requiring prospective randomized controlled trials with intensive phenotyping also for identifying
strategies for its risk assessment, prevention and treatment.
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Introduction
Statins are highly effective drugs on lowering plasma low-den-
sity lipoprotein (LDL) cholesterol by competitively inhibiting
hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, an
enzyme catalysing the rate-limiting step in the mevalonate
pathway. Their action takes placemainly in the liver, where LDL
receptors are increased due to the decreased hepatocyte choles-
terol. Other effects include the modest increase in high-density
lipoprotein (HDL) cholesterol and minor decrease of plasma
triglycerides [1]. Next to these lipid-lowering effects, statins
increase stability of the atherosclerotic plaques, decrease
inflammation and oxidative stress and improve endothelial
function [2]. Taken together these different ‘pleiotropic’ actions
are likely responsible for the lower risk of cardiovascular
morbidity and mortality of statin-treated patients even in the
primary prevention setting [3].
Although statins are generally consideredwell-tolerated, their
wide use has shed light on adverse effects that can result to
intolerance and discontinuation of the treatment. Aside from
elevation of liver enzymes and risk of incident diabetes, themost
common side effect is myotoxicity. Mild muscle symptoms are
reported in 10–20% of the patients treated with statins in large
community based studies [4–6]. The term ‘myopathy’ defines a
wide range of muscular symptoms, whereas ‘myositis’ demands
the increase of creatine kinase (CK) levels,with ‘rhabdomyolysis’
being themost life-threatening formwith excessive CK elevation
as a result of massive muscle destruction and myoglobinuria.
However, the incidence of rhabdomyolysis during statin treat-
ment is very low (0003–01%) [5–7]. The wide range of reported
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data on the incidence may be due to the lack of standardized
clinical diagnostic criteria for statin-related adverse events. Of
note, CK elevation is not generally considered to be required for
treatment discontinuation, when patients claim muscle pain [8].
There are several mechanisms that are proposed to be
involved in the statin-induced myopathy. Statin-induced inhi-
bition of HMG-CoA reductase also results in the lowering of
several other intermediates of the pathway, such as dolichols,
prenylated proteins and electron transport chain proteins,
heme A and ubiquinone (coenzyme Q10, CoQ10), which shut-
tles between complex I and II (CI and CII) of the mitochondrial
electron transport chain (ETC.). The frequent observation of
decreased concentrations of CoQ10 not only in the circulation,
but also in skeletal muscle of statin-treated humans and rodents
[9], has led to the suggestion that statins may interfere with
mitochondrial function, which could in turn impair muscle
function and damage muscle morphology.
The aim of this review was to summarize studies in cell lines,
animal models and humans on the impact of statins on the key
features of muscle mitochondrial morphology and function both
in vivo and in vitro. Furthermore, this review includes studies on
possible mechanistic interactions between muscle mitochondria
and statin-induced myopathy. Finally, risk factors for muscle
statin intolerance are also briefly discussed. There have been
previous reviews addressing related topics [4,6,9–11].
To this end, we identified publications in English language
referring to statin treatment and muscle adverse events via a
PubMed search until December 2014. Publications specifically
addressing the relationship between statin treatment and
mitochondrial function impairment were analysed in detail.
The PubMed search was performed using the following com-
binations of the terms: ‘statin AND mitochondria AND myop-
athy AND human, animal, cell cultures’, respectively. We
identified 22 original papers on humans, 19 publications on
animal models, 10 publications in cell cultures and 13 reviews.
We included only these studies, which reported data on ubi-
quinone content, mitochondrial morphology and mitochondrial
complex activity. We excluded all studies that examined statin
effects on mitochondria in tissues other than skeletal muscle or
focused on muscle fibre alteration rather than reporting data on
mitochondrial function. We finally included 12 original papers
on humans, five on animal models, five on cell cultures and
eight reviews meeting the criteria. Additional publications
were identified from the reference list of the retrieved publi-
cations or from authors’ knowledge.
Possible mechanisms of statin-induced
myopathy not directly linked to mitochondria
Cholesterol is a basic component of the cell membrane, contrib-
uting to its stability. Its reduction by statins results in changes in
membrane fluidity and modification of muscle membrane sus-
ceptibility. Membrane alterations can modulate the function of
sodium, potassium and chloride channels, subsequently dam-
aging myocytes and causing myopathy [12,13] (Fig. 1).
Statins also inhibit farnesyl pyrophosphate and geranylger-
anyl pyrophosphate, intermediates of the mevalonate pathway,
which are involved in the post-translational modification of
proteins such as small GTPases and lamins. GTPases and
lamins play an important role in cell maintenance and
chromatin organization (Fig. 1). Dysprenylation of small GTP-
ases has been shown to result in muscle fibre degeneration and
apoptosis, whereas lamin dysprenylation may result in fragile
nuclear membranes and induce muscle cell apoptosis [14,15].
Dolichols, other intermediates of the mevalonate pathway,
promote protein N-glycosylation. Inhibition of their production
by statins impairs the expression of receptors and the produc-
tion of structural proteins, which may also lead to myopathy
[12,15] (Fig. 1). Treatment of pre-adipocytes with 10 nmol/L
cerivastatin resulted in impaired production of structural pro-
teins and receptors with accumulation of proreceptors and
apoptosis after prolonged exposure [16], suggesting disruption
of N-glycosylation, as the mechanism underlying cell damage.
Statins have been also associated with increased expression of
atrogin-1, a gene linked to muscle atrophy [17]. Atrogin-1
expression occurs early during the development of muscle
atrophy, and its increase precedes the loss of muscle mass. Of
note, patients with statin-associated myopathy exhibit increased
mRNA levels of atrogin-1 in biopsies of quadriceps muscle [18].
The role of CoQ10 during statin treatment
The impact of mitochondria on statin-induced myopathy orig-
inally derived from the finding of lower CoQ10 in the circula-
tion and skeletal muscle of statin-treated patients and higher
lactate/pyruvate ratios, as indicator of abnormal mitochondrial
function [19,20]. CoQ10 is a basic electron transporter of the
respiratory chain of the mitochondria and the end product of
the mevalonate pathway.
Several studies reported a decrease in plasma CoQ10 levels
in statin-induced myopathy, as recently reviewed [9]. However,
the reported decreases in CoQ10 levels may be due to the
simultaneous reduction of LDL cholesterol, which is the main
transporter of CoQ10 in the circulation [9]. There also seems to
be a statin type-specific influence on CoQ10 levels, as rosu-
vastatin but not atorvastatin was found to preserve CoQ10
levels in patients with coronary artery disease, when each drug
was combined with aerobic exercise. However, this study did
not include a control group treated with the statins or exercise
only [21]. Lower plasma CoQ10 levels do not generally reflect
lower muscle CoQ10 levels, as demonstrated by contradictory
results of skeletal muscle biopsies [22–24].
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Thus, it is not surprising that the supplementation with
CoQ10 to prevent or treat statin-induced myopathy revealed
contradictory results. Some studies showed that CoQ10
administration can increase CoQ10 blood levels in statin-trea-
ted patients [25–28]. Two studies on the frequency of myo-
pathic symptoms reported improvement of statin-related
muscle complaints upon CoQ10 (240 mg/day) coadministration
in patients with gastric adenocarcinoma treated with high-dose
lovastatin (35–45 mg/kg/day) [29,30]. However, the absence of
control groups and data from muscle biopsies prevents us from
drawing conclusions on the benefit of CoQ10 administration in
these specific patient cohorts. Most reviews, finally, do not
support any benefit from CoQ10 supplementation when com-
pared to placebo in patients on usual statin doses [9,10,31–33].
One recent study examined the effect of 600 mg/d CoQ10
supplementation on myopathic symptoms of patients assigned
to 20 mg/d simvastatin. Myopathy appeared irrespective of the
assignment to CoQ10 treatment [34]. Of note, current guide-
lines or position statements do not recommend CoQ10 sup-
plementation to increase adherence to statin treatment [8,35].
Possible mechanisms of statin-induced
myopathy directly linked to mitochondria
Next to the lowering CoQ10 levels, statins were suggested to
exert direct effects on the ETC., as pravastatin accelerated the
age-dependent impairment of CI function in rat muscle cells
[36].
Furthermore, impaired calcium signalling could also con-
tribute to statin-induced myopathy. Statins are proposed to
induce mitochondrial depolarization and calcium release
resulting in cytoplasmic calcium waves with subsequent cal-
cium release by the sarcoplasmic reticulum as a possible
mechanism of caspase activation and induction of apoptosis
[9,15,37–39] (Fig. 1). The cytosolic calcium increase may also
raise Ca2+- and phospholipid-dependent protein kinase C (PKC)
activity, which promotes closing of the chloride channel 1, CLC-
1, resulting in membrane hyperexcitability, as shown in muscles
of rats chronically treated with fluvastatin or atorvastatin [40].
Moreover, there is evidence of increased lipid peroxidation
and oxidative stress after statin treatment. Exposing primary
Figure 1 Possible mechanisms of statin-induced myopathy. Statin-treated patients feature lower cholesterol synthesis and
production of prenylated proteins and dolichols, which can lead to membranolysis and/or apoptosis in skeletal muscle. Impaired
mitochondrial function and elevated ROS can result from reduced CoQ10 content, as well as inhibition of the electron transport
chain and of beta oxidation. Finally, increased intracellular calcium levels due to accelerated mitochondrial MPT pore opening can
also cause apoptosis or via PKC inhibit CLC-1 channels with consecutive hyperexcitability of the cytoplasmic membrane. HMG-CoA:
hydroxymethylglutaryl-coenzyme A, PKC: protein kinase C, CLC-1: chloride channel protein-1, CoQ10: coenzyme Q10, cyt c:
cytochrome c, ROS: reactive oxygen species, TCA cycle: tricarboxylic acid cycle, MPT pore: mitochondrial permeability transition
pore.
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human muscle cells to simvastatin for 48 h resulted in impaired
ADP-stimulated mitochondrial respiration, increased reactive
oxygen species (ROS) production and activation of apoptosis
[41] (Fig. 1). In contrast, statins may exert opposite effects on
cardiac muscle mitochondria by enhancing PGC-1a expression
and lowering ROS production [42], whereas oxidative capacity
appeared to be decreased in skeletal muscle of statin-treated
patients.
Studies on the effects of statins on muscle
mitochondria and energy metabolism
The effects of statins on muscle energy metabolism have been
studied in cell cultures (Table 1), animal models (Table 2) as
well as in humans (Table 3). The most interesting features
tested in cell cultures were mitochondrial membrane potential,
maximal oxygen uptake and ATP levels. In animal models and
human studies, muscle CoQ10 levels have been also measured
in addition to assessing mitochondrial enzyme activities and
ROS production.
Studies in cell cultures
Few studies have examined the effect of statin application on
cell cultures, mainly providing indications for a mitochondrial
mechanism involved in muscle cell apoptosis (Table 1).
Exposure of rat L6 cell lines to cerivastatin, fluvastatin, ator-
vastatin, simvastatin but not pravastatin decreases glutamate-
driven state 3 respiration and respiratory control, and lowered
beta oxidation and DNA fragmentation by 88–96% indicating
that lipophilic statins mainly impair mitochondrial function,
with pravastatin being less toxic [43]. In C2C12myotubes but not
HepG12 cells, simvastatin decreased mitochondrial membrane
potential and oxygen consumption [44]. This was attributed to
impaired insulin growth factor-1/protein kinase B (Igf-1/Akt)
signalling leading to abnormal mitochondrial function, whereas
some liver cell lines may be protected by intact Igf-1/Akt
signalling.
In differentiated primary human skeletal muscle cells, sim-
vastatin decreased maximal oxygen consumption, promoted
mitochondrial PTP opening and increased levels of Bax and
Bcl-2 proteins, in line with impaired complex I respiration [41].
Another study in human rhabdomyosarcoma cells treated with
simvastatin showed a decrease in ATP levels, which was
reversed by the application of ubiquinone [45]. These data
provide evidence for impaired mitochondrial function, which
can be reversed by CoQ10 at least in cell cultures.
Studies in animal models
Although studies in several animal models have confirmed
muscle injury upon statin treatment, they did not consistently
support the concept of compromised muscle mitochondrial
function (Table 2).
Treating male rabbits with simvastatin and pravastatin
resulted in decreased muscle ubiquinone content, but did not
affect mitochondrial enzyme activities [46]. Interestingly, ceri-
vastatin but not pravastatin treatment of female rats for 15 days
raised serum CK levels and induced muscle necrosis along with
swollen mitochondria, while mitochondrial enzyme activities
were unchanged [47]. Nevertheless, another study on treating
Table 1 Parameters of mitochondrial function studied in cell cultures
Reference Statin (name, dose) Cell type Findings
Sirvent et al. [39] S Rat skinned skeletal muscle Inhibition of CI
Kaufmann et al. [43] C, F, A, S, P 100 mmol/L L6 cells S,F,A: 46–65% ↓ Mitochondrial membrane
potential, C,S,F,A:↓Respiratory control
ratio, ↓Glutamate-driven state 3 respiration,
88–96%↓ b oxidation, DNA fragmentation
mitochondrial swelling
Mullen et al. [44] S, 20 lmol/L for 72 h Primary mouse skeletal muscle
myocytes, C2C12 myotubes
and liver HepG2 cells
↓Mitochondrial membrane potential, ↓O2
consumption and Akt PY in C2C12 myotubes
but not in HepG2 cells
Kwak et al. [41] S, 50 lmol/L
S, 50 lmol/L+ mevalonate
50 lmol/L for 48 h
Differentiated primary human
skeletal muscle cells
S: 32–27%↓Maximal ADP-stimulated O2
consumption
↑Protein levels of Bax and Bcl-2
Vaughan et al. [45] S, 5, 10 lmol/L
S, 5 lmol/L +ubiquinone
05, 10 lmol/L for 24 h or 48 h
Rhabdomyosarcoma cells S: ↓ mito staining, ↓ATP
Ubiquinone reverses suppression
at 10 lmol/L
S, simvastatin; A, atorvastatin; C, cerivastatin; P, pravastatin; F, fluvastatin; C I, complex I; Akt PY, protein kinase B phosphorylation; ATP, adenosintriphosphate;
ADP, adenosindiphosphate; Bcl-2 protein, B-cell lymphoma-2 protein; Bax, Bcl-2-associated protein.
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rats with cerivastatin documented type I fibre muscle injury
and swollen mitochondria prior to the onset of muscle necrosis
suggesting early involvement of mitochondria in the develop-
ment of statin-induced myopathy [48]. Moreover, 2-weeks
treatment with atorvastatin increased ROS production and
decreased PGC-1a expression in rat skeletal muscle cells, pro-
viding evidence for decreased mitochondrial biogenesis and
augmented oxidative stress [42]. Of note, these authors also
found that endurance training of the rats improved mitochon-
drial respiration and oxidative capacity and protected the
skeletal muscle mitochondria against statin exposure [49]. Also,
mevalonate recovers abnormalities in skeletal muscle mor-
phology rapidly within 24 h in a C. elegans hmgr-1 mutant,
which lacks HMG-CoA reductase and can therefore serve as a
model of statin treatment [50].
Studies in humans
Several studies examined the effect of statins on skeletal muscle
of patients treated with different statins at various doses. Some
studies specifically examined the effect of statins on mito-
chondrial function in muscle biopsies in statin-treated patients
with or without signs of myopathy as well as in control persons
[22–24,42,51–57] (Table 3).
Lactate/pyruvate ratios were found to be significantly higher
in patients treated with statins compared to controls, a finding
that provided the first evidence that statin therapy may be
associated with abnormal mitochondrial metabolism [19]. In
three patients with symptoms of myopathy likely related to
statin use, muscle biopsies showed abnormally elevated lipid
stores, ragged red fibres and fibres with decreased staining for
cytochrome c activity, a biomarker of mitochondrial activity
[58]. These abnormalities disappeared after withdrawal of the
statin. The retrospective design accounts for the lack of biopsies
at baseline and the absence of a control group of patients with
myopathy unrelated to statin use and represents a shortcoming
of this study. Comparing treatment of 80 mg/day simvastatin
with that of 40 mg/day atorvastatin for 8 weeks showed a 30%
decrease of muscle CoQ10 in the simvastatin group along with
decreased ETC. enzyme activities and apparently 39% lower
plasma CoQ10 levels in the atorvastatin group [22]. Three other
studies on simvastatin, atorvastatin or placebo treatment found
lower muscle CoQ10 levels in the simvastatin-treated groups
[23,24,59]. Hypercholesterolaemic patients on simvastatin
treatment (10–40 mg/day) had lower muscle content of ubi-
quinone and CIV activity along with decreased maximal ex vivo
oxidative capacity [23]. Of note, mitochondrial content was
comparable in the simvastatin-treated group and control
groups. Strengths of this study are its well-matched control
group and the use of established methods for assessment of
mitochondrial CoQ10 content and mitochondrial function. In 48
patients assigned to simvastatin 80 mg/day, atorvastatin
40 mg/day or placebo for 8 weeks, muscle CoQ10 decreased in
the simvastatin group only and mtDNA/nDNA ratio fell by
47% in both statin-treated groups suggesting lower mitochon-
drial density [24]. A small study in patients presenting with
myopathic symptoms during statin treatment revealed signs of
abnormal mitochondrial function, such as subsarcolemmal
Table 2 Parameters of mitochondrial function studied in animal models
Reference Statin (name, dose)
Duration
in days Animal model Findings
Nakahara et al. [46] S, 100 mg/kg/day
P, 100 mg/kg/day
P, 200 mg/kg/day
+ 300 mg/kg/day
28
28
21/21
Male New Zealand
white rabbits
S: ↑CK, muscle necrosis, ↓ Ubiquinone
content = Mitochondrial enzyme activities
in all groups
Schaefer et al. [47] C, 01, 05, 10 mg/kg/day 15 Female Sprague-Dawley
Crl: CD(SD)IGSBR rats
↑CK, muscle necrosis, inflammation
at higher dose
Altered mitochondria in fibres with
degeneration
Obayash et al. [48] C, 2 mg/kg/day 10 F344 rats Necrosis of soleus muscle fibres, prior to
manifestation swollen mitochondria
Bouitbir et al. [42] A, 10 mg/kg/day 14 Male Wistar rats ↑ROS in skeletal muscle, ↓PGC-1 a expression
Ranji et al. [50] – – C. elegans hmgr-1 mutant
(lacks HMG-CoA reductase)
Defective mitochondrial morphology,
protein prenylation
Reversible with mevalonate within 24 h
S, simvastatin; A, atorvastatin; C, cerivastatin; P, pravastatin; CK, creatine kinase; ROS, reactive oxygen species; PGC-1 a, peroxisome proliferator-activated
receptor gamma coactivator 1-a.
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accumulation of mitochondria, lipid increase and Cox negative
fibres [59].
However, not all studies come to the conclusion that muscle
mitochondrial function is impaired due to statin treatment. Six
months of simvastatin treatment (20 mg/day) neither resulted
in changes from baseline in CoQ10 levels nor in high-energy
phosphate concentrations in skeletal muscle biopsies, com-
pared to the untreated control persons [60]. While this was
explained by the rather low dose of simvastatin used, another
albeit retrospective analysis of muscle biopsies obtained from
23 patients with statin-related myopathy compared to those of
patients with statin-unrelated myopathy found no direct asso-
ciation with statins [56]. Nevertheless, muscle mtDNA was
lower in patients with statin-induced myopathy, but there was
no difference between both groups in mtDNA deletion score or
oxidative mtDNA damage, suggesting that the observed
mtDNA depletion did not lead to qualitative damage of muscle
mitochondria. A limitation of this study is the absence of data
on baseline mtDNA content.
Another study assessed mitochondrial biogenesis and oxi-
dative stress from ROS production and PGC-1a and PGC-1b
gene expression in skeletal and cardiac muscle cells of patients
Table 3 Parameters of mitochondrial function studied in humans
Reference Cohort (n, diagnosis)
Statin
(name, dose)
Duration in
months
Muscle
CoQ10 Other findings
Paiva et al. [22] 48 hypercholesterolaemia S, 80 mg/day
A, 40 mg/day
2 30% in S S: ↓ CI, II, III, IV, CS 30% ↓ CoQ10
A: 39% ↓ CoQ10
Lamperti et al. [51] 18 hypercholesterolaemia
with myopathic symptoms
S, C, A,
R 5/10/20 mg/day
n. r. in 10 pts Cytochrome c oxidase-negative
ragged red fibres in 2 pts
Guis et al. [52] 11 hypercholesterolaemia
with statin-induced CK
elevation 8 healthy
A, 10 mg/day
S, 5-20 mg/day
C, 10 mg/day
P, 5–20 mg/day
F, 10 mg/day
n. r. – = cytochrome oxidase activity,
PCr recovery
F,S,A,P,S: Abnormal in vitro
contracture tests in 7 pts
Schick et al. [24], 48 hypercholesterolaemia S, 80 mg/day
A, 40 mg/day
Placebo
2 in S S: 47%
↓ mtDNA/nDNA
Traustadottir et al. [53] 12 healthy men and
women, LDL > 130 mg/dl
S, 80 mg/day 3 – = VO2max, RER, O2 uptake kinetics
Wu et al. [54] 10 hypercholesterolaemia S, 20 mg/day 1 – ↓PCr recovery
Bouitbir et al. [42] 5 statin-induced myopathy A, 10 mg/day
R, 10 mg/day
S, 10–20 mg/day
6-60 – A,R,S:↑ROS, ↓PGC-1a, ↓PGC-1b
Mikus et al. [55] 37 with > 2 metabolic
syndrome risk factors
S, 40 mg/day 3 – S: 4.5%↓ CS
=VO2max/kg
Stringer et al. [56] 23 statin-induced myopathy S > 80 mg/day,
< 80 mg/day
A > 40 mg/day
n. r. S: ↓mtDNA, ↓mtDNA/nDNA
Larsen et al. [23] 10 hypercholesterolaemia S, 10–40 mg/day 60 in S ↓C, IV
=mito content
OXPHOS
Parker et al. [57] 420 healthy A, 80 mg/day 6 – ↑muscle complaints
=muscle strength
VO2max
S, simvastatin; A, atorvastatin; C, cerivastatin; R, rosuvastatin; P, pravastatin; F, fluvastatin; CoQ10, coenzyme Q10; PCr recovery, phosphocreatine recovery; pts,
patients; CK, creatine kinase; mtDNA, mitochondrial DNA; nDNA, nuclear DNA; LDL, low-density lipoprotein; VO2max, maximal oxygen uptake; RER, respiratory
exchange ratio; ROS, reactive oxygen species; PGC-1 a, b, peroxisome proliferator-activated receptor gamma coactivator 1- a, b; n.r, not reported; OXPHOS,
oxidative phosphorylation; ATP, adenosintriphosphate.
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treated with statins. Here, the five patients with statin-induced
myopathy exhibited increased ROS production and decreased
PGC-1a and PGC-1b gene expression [42]. This study provides
evidence for a different mechanism of statin action on skeletal
and cardiac muscle mitochondria. In cardiac muscle cells, ROS-
induced PGC-1 family expression was stimulated, whereas in
skeletal muscle cells, which lack sufficient antioxidant mecha-
nisms, the oxidative damage prevailed. Using animal models
and cell cultures allowed for comprehensive investigation of
the possible mechanisms of statin action.
Only few studies employed non-invasive in vivo techniques
to quantify submaximal oxidative capacity, such as spiroerg-
ometry and 31P magnetic resonance spectroscopy. Two spir-
oergometry studies found no changes of maximal oxygen
uptake (VO2max) and oxygen uptake kinetics after 12 weeks of
simvastatin treatment (80 mg/day) in 10 patients [53] or after
6 months of atorvastatin (80 mg/day) when compared with
placebo [57]. Of note, CK levels and muscle symptoms were
higher in the atorvastatin group despite unchanged parameters
of exercise performance after 6 weeks of atorvastatin treatment.
However, these studies lack efficient control of exercise moni-
toring during the intervention period, as well as data from
intramuscular CoQ10 levels, because no muscle biopsies were
performed. Interestingly, an exercise training study provided
some evidence for reduced physical performance after statin
use [55]. This study randomized patients, who had features of
the metabolic syndrome, to aerobic training with or without
simvastatin (40 mg/day) for 12 weeks. VO2max increased by
10% in the statin-free group, but only by 15% in the statin-
treated group, which also showed a small 45% decrease in
muscle citrate synthase enzyme activity, a marker of mito-
chondrial density and/or activity. A limitation of this study
resides in the lack of placebo administration in the control
group performing exercise only. Nevertheless, statins may
blunt the beneficial effect of exercising on cardiorespiratory and
muscular fitness via interfering with mitochondria.
While spiroergometry yields a rather indirect measure with
several limitations, measurement of the half-time of muscle
phosphocreatine (PCr) recovery upon exercise-induced PCr
depletion using 31P magnetic resonance spectroscopy provides
a direct measure of submaximal mitochondrial oxidative
capacity [61]. Using this method, simvastatin (20 mg/day)
treatment for 4 weeks led to prolonged, that is impaired PCr
recovery time in 10 hypercholesterolaemic patients [54]. In this
study, four of five patients with prior statin use experienced
myalgia suggests a bias in the patient selection, as the symptom
frequency is not representative for the general population
treated with statins. Another study reported normal PCr
recovery times in statin-treated patients and suggested that
myoskeletal symptoms may become evident only in the pres-
ence of altered calcium homoeostasis [52]. However, the small
sample size with only 11 patients treated with various doses of
five statins for an unreported period of time makes it difficult to
compare the different statins and doses.
Risk factors for statin-induced myopathy
It is clinically relevant to detect factors that increase the risk of
statin-induced myopathy in order to identify persons at risk
and/or to adjust or modify the treatment of such patients.
Increasing age [62], female gender [63], renal insufficiency,
subclinical hypothyroidism and polypharmacy have been
related to increased risk of statin-induced myopathy [10,11,64].
Other risk factors include high levels of physical activity,
alcohol and drug abuse, HIV infection, severe trauma and
surgery with increased metabolic demands [10].
In addition, genetic factors may also play a role by increasing
the susceptibility of some patients to adverse effects of statins.
The SLCO1B1 gene encodes a protein responsible for the
hepatic uptake of statins, and polymorphisms in this gene are
tightly associated with statin-induced myopathy [65,66]. Also,
polymorphisms in genes of the cytochrome P450 system
(CYP2D6, CYP3A4, CYP3A5) and efflux transporters (ABCB1,
ABCG2) have been studied in this context [66]. CYP2D6 gene
polymorphisms have been associated with increased suscepti-
bility to atorvastatin-induced muscle side effects [67]. Several
mutations in the PYGM gene (McArdle’s disease), CPT-II
deficiency and AMPD1 gene as well as the ryanodine receptor 1
(RYR1) gene have also been associated with increased risk and
severity of statin-associated myopathy [68,69].
Specifically, patients with inherited mitochondrial diseases,
such as mitochondrial myopathy, encephalopathy, lactic aci-
dosis and stroke-like episodes (MELAS syndrome) [10],
myoadenylate deaminase (MADA) deficiency and variations of
the CoQ10 gene appear to have higher susceptibility for statin-
associated myopathy [70]. Polymorphisms of the CoQ2 gene,
which is important for the CoQ10 synthesis, are associated with
primary CoQ10 deficiency and severe mitochondrial myopathy
[65]. But even mild variants of this gene were associated to
increased susceptibility of the carriers for statin-induced
myopathy. On the other hand, statin treatment per se can
induce MELAS-like syndrome in vulnerable individuals [71].
Of note, a case report of a woman with MELAS syndrome due
to A3243G mutation showed marked reduction not only of
insulin secretion but also of muscle ATP synthesis at baseline
and during insulin stimulation [72]. Another case report of a
teenager with the A3243G mutation, which accounts for more
than 80% of the mutations found in MELAS syndrome patients,
showed that statin treatment led to increased CK levels and
myopathic symptoms despite normal CoQ10 levels and respi-
ratory chain enzyme activities [73]. This suggests that direct
effects of statins on mitochondria do not necessarily explain
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increased susceptibility in all patients with mitochondrial
diseases.
Statin dose and properties are important determinants of
myotoxicity, with higher lipophilicity and interaction with drug
metabolizing pathways such as CYP increasing risk for adverse
muscle [11,74]. A recent study also showed that individuals
with 25-OH vitamin D3 below 15 mg/mL on statin had a
higher incidence of muscle adverse effects compared to those
without statin, providing some evidence that vitamin D defi-
ciency also represents another risk condition for muscle
adverse effects in patients treated with statins [75].
Of note, patients with diabetes mellitus and/or obesity seem
to be at greater risk of statin-related adverse events. Among
patients with diabetes, statin use was associated with 29%
higher risk for statin-associated myopathy [76]. In the SEARCH
trial using treatment with 80 mg/day simvastatin, diabetes at
baseline was associated with ‘definite or incipient myopathy’
with an overall relative risk of 17 and a relative risk of 23 after
1 year [77]. Overall statin-associated complications were also
more frequent in patients with body mass index (BMI) above
29 kg/m2 [78]. Given the increasing prevalence of diabetes and
obesity, studies on statin-related adverse events should specif-
ically address obese patients with type 2 diabetes in future
studies.
Conclusions
This review focused on the effect of statins on mitochondrial
function in cell cultures, animal models and humans. It remains
unclear whether or not impaired mitochondrial function is a
consistent result of statin treatment and involved in statin-
associated myopathy. Most available studies suffer from certain
limitations, such as including small cohort size, inconsistencies
in the diagnostics of statin-associated myopathy and applica-
tion methods, which do not allow for exact assessment of
mitochondrial function. Larger prospective randomized con-
trolled trials on a multinational level with specific phenotyping
are therefore needed for the better understanding of the path-
ogenesis of statin-induced myopathy and the role of muscle
mitochondrial function. Intensified and standardized pheno-
typing including detailed assessment of mitochondrial function
as well as genetic screening, mRNA and proteomic finger-
printing are likely the most promising strategies for the iden-
tification of persons susceptible to adverse muscle effects of
statins. These measures would support guidelines regarding
effective statin use and thereby promote prevention, reversal
and treatment of unwanted effects of statins.
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